PARP inhibitor |
PARP inhibitors have been used successfully as medicine for HR deficiency, a defect in cell’s DNA repair machinery usually found in most cancers. However, detection of the deficiency is very difficult because the standard genetic test used in the clinic does not reliably detect cancer-causing HR deficiency.
A scientist from Harvard medical school has designed an algorithm called SigMA that can successfully read the molecular signature of the cancer-driving defect, HR deficiency. This could help identify patients who could benefit from treatment with PARP inhibitors.
This is a big step towards personalized therapy for cancer.
Reference:
Comments
Post a Comment
Leave your comment about the post